Perrigo names president and CEO
A publicly traded drug maker in the region has named its new president and CEO.
Dublin-based Perrigo Company, which operates its North American headquarters in Allegan, said today Uwe Röhrhoff, former CEO at the Düsseldorf, Germany-based manufacturer Gerresheimer AG, has been appointed president, CEO and board member, effective Jan. 15, 2018.
Current CEO John Hendrickson, who announced his retirement last June, will remain with the company until March 15 to ensure a smooth transition.
Laurie Brlas, Perrigo chair, said the board chose Röhrhoff for his experience and reputation.
“Uwe brings a strong track record of operational excellence, strategic growth and health care supply chain management,” Brlas said.
“As the CEO of Gerresheimer AG, a publicly traded international manufacturer for the global pharmaceutical and health care industries, Uwe’s transformative strategic vision and focus on operational excellence enhanced the company’s leading market positions and created significant value for shareholders of approximately 225 percent in total shareholder return.”
Brlas said Perrigo is grateful to Hendrickson for his years of “contributions to the company over the past 28 years.”
“John has been a trusted leader, a great colleague and a friend to many, and we value his continued guidance as Uwe transitions into his new role.”
Röhrhoff said he’s looking forward to his opportunities at Perrigo.
“I have long admired Perrigo’s operational excellence and its mission to deliver high-quality, affordable health care products that improve the lives of patients and families,” Röhrhoff said. “I see great opportunity to leverage the company’s unique asset base and to lead its talented employees to deliver enhanced value for shareholders.”
Röhrhoff has more than 25 years of experience with Gerresheimer AG, a leading global manufacturer of pharmaceutical and cosmetic packaging products and medical devices for the storage, dosage and safe administration of drugs, which generated about €1.4 billion, or $1.6 billion, in revenue in 2016.
He began his career with Gerresheimer AG in 1991, advancing within the organization to serve in a number of key leadership roles in Europe and North America.
Röhrhoff was appointed to build out the company’s business in the U.S. (1996-1998) and head the American subsidiary Gerresheimer Glass (2001-2010). He served as an executive board member (2003-2017), responsible for two of the company's three business units, and CEO (2010-2017) of Gerresheimer AG until his retirement in August.
He earned a business administration degree from the University of Cologne.
Hendrickson was appointed as CEO of Perrigo in April 2016 and to the board of directors in June 2016.
During his tenure as CEO, the company implemented global workforce reductions of 14 percent, divested itself of several businesses in multi-million-dollar and multi-billion-dollar transactions and restructured its board at the behest of an investor in order to bring “fresh perspectives” to the company.
He also served as the company’s president from October 2015 until April 2016.
In his 25-year career at Perrigo, Hendrickson held a number of other roles: EVP of global operations and supply chain; EVP and general manager of Perrigo Consumer Healthcare; EVP of operations; VP of manufacturing; VP of customer service; director of engineering; and process engineering manager.
Previously, Hendrickson held a leadership position at Procter & Gamble.
Perrigo Company (NYSE: PRGO; TASE: PRGO), a global over-the-counter, or OTC, consumer goods and pharmaceutical company, was founded in Allegan in 1887 as a packager of generic home remedies.
Now headquartered in Dublin, the company makes OTC products and supplies infant formulas and topical medications across a variety of product categories and geographies in North America, Europe and Australia, as well as Israel and China.